Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial

<p>Abstract</p> <p>Purpose</p> <p>To evaluate a panel of pretreatment clinical and laboratory parameters in metastatic melanoma (MM) in order to verify their impact on response and survival in a single prospective multi-institutional phase III study comparing out-patien...

Full description

Bibliographic Details
Main Authors: Casamassima Addolorata, Brugnara Salvatore, Freschi Antonio, Labianca Roberto, Romanini Antonella, Sileni Vanna, Ravaioli Alessandra, Guida Michele, Lorusso Vito, Nanni Oriana, Ridolfi Ruggero
Format: Article
Language:English
Published: BMC 2003-12-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/1/1/13
id doaj-c7cfc047941c4a5b884ef5ffb699308b
record_format Article
spelling doaj-c7cfc047941c4a5b884ef5ffb699308b2020-11-24T21:52:51ZengBMCJournal of Translational Medicine1479-58762003-12-011113Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialCasamassima AddolorataBrugnara SalvatoreFreschi AntonioLabianca RobertoRomanini AntonellaSileni VannaRavaioli AlessandraGuida MicheleLorusso VitoNanni OrianaRidolfi Ruggero<p>Abstract</p> <p>Purpose</p> <p>To evaluate a panel of pretreatment clinical and laboratory parameters in metastatic melanoma (MM) in order to verify their impact on response and survival in a single prospective multi-institutional phase III study comparing out-patient chemotherapy (CT) vs bioCT.</p> <p>Methods</p> <p>A total of 176 patients were randomised to receive CT (cisplatin, dacarbazine, optional carmustine) or bioCT (the same CT followed by subcutaneous IL-2 plus intramuscular α-IFN-2b). Pretreatment total leucocytes, lymphocytes, eosinophyls, C-reactive protein (CRP), lactate dehydrogenase (LDH), erytrosedimentation rate (ESR), and fibrinogen were analyzed. Some clinical parameters (performance status, age, sex, and disease site) were also considered. As we found a positive trend for bio-CT with no statistical significance in OR (25.3% vs 20.2%) and OS (11 Mo vs 9.5 Mo), all analyses are stratified by treatment arm.</p> <p>Results</p> <p>In univariate analysis, higher value of lymphocytes percentage (P < .0001), lower value of total leucocytes (P=.005), CRP (P=.003), LHD (P < .0001), ESR (P < .027), fibrinogen (P < .0001), and no liver disease were strongly related to a better survival. In a multivariate analysis, using the Cox proportional hazards model, only fibrinogen (P=.004), LDH (P=.009) and liver disease (P=.04) were found to have an independent role on clinical outcome in metastatic melanoma patients.</p> <p>Conclusion</p> <p>Liver disease and higher LDH and fibrinogen levels had an important impact on survival in MM patients. In particular, fibrinogen has been recently reconsidered both for its determinant role in the host hemostatic system, and for its capability to provide protection against NK and LAK-cell-induced lysis. These observations could have some important implications for therapeutic approaches, in particular when immunological strategies are used.</p> http://www.translational-medicine.com/content/1/1/13
collection DOAJ
language English
format Article
sources DOAJ
author Casamassima Addolorata
Brugnara Salvatore
Freschi Antonio
Labianca Roberto
Romanini Antonella
Sileni Vanna
Ravaioli Alessandra
Guida Michele
Lorusso Vito
Nanni Oriana
Ridolfi Ruggero
spellingShingle Casamassima Addolorata
Brugnara Salvatore
Freschi Antonio
Labianca Roberto
Romanini Antonella
Sileni Vanna
Ravaioli Alessandra
Guida Michele
Lorusso Vito
Nanni Oriana
Ridolfi Ruggero
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
Journal of Translational Medicine
author_facet Casamassima Addolorata
Brugnara Salvatore
Freschi Antonio
Labianca Roberto
Romanini Antonella
Sileni Vanna
Ravaioli Alessandra
Guida Michele
Lorusso Vito
Nanni Oriana
Ridolfi Ruggero
author_sort Casamassima Addolorata
title Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
title_short Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
title_full Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
title_fullStr Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
title_full_unstemmed Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
title_sort fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: imi (italian melanoma inter-group) trial
publisher BMC
series Journal of Translational Medicine
issn 1479-5876
publishDate 2003-12-01
description <p>Abstract</p> <p>Purpose</p> <p>To evaluate a panel of pretreatment clinical and laboratory parameters in metastatic melanoma (MM) in order to verify their impact on response and survival in a single prospective multi-institutional phase III study comparing out-patient chemotherapy (CT) vs bioCT.</p> <p>Methods</p> <p>A total of 176 patients were randomised to receive CT (cisplatin, dacarbazine, optional carmustine) or bioCT (the same CT followed by subcutaneous IL-2 plus intramuscular α-IFN-2b). Pretreatment total leucocytes, lymphocytes, eosinophyls, C-reactive protein (CRP), lactate dehydrogenase (LDH), erytrosedimentation rate (ESR), and fibrinogen were analyzed. Some clinical parameters (performance status, age, sex, and disease site) were also considered. As we found a positive trend for bio-CT with no statistical significance in OR (25.3% vs 20.2%) and OS (11 Mo vs 9.5 Mo), all analyses are stratified by treatment arm.</p> <p>Results</p> <p>In univariate analysis, higher value of lymphocytes percentage (P < .0001), lower value of total leucocytes (P=.005), CRP (P=.003), LHD (P < .0001), ESR (P < .027), fibrinogen (P < .0001), and no liver disease were strongly related to a better survival. In a multivariate analysis, using the Cox proportional hazards model, only fibrinogen (P=.004), LDH (P=.009) and liver disease (P=.04) were found to have an independent role on clinical outcome in metastatic melanoma patients.</p> <p>Conclusion</p> <p>Liver disease and higher LDH and fibrinogen levels had an important impact on survival in MM patients. In particular, fibrinogen has been recently reconsidered both for its determinant role in the host hemostatic system, and for its capability to provide protection against NK and LAK-cell-induced lysis. These observations could have some important implications for therapeutic approaches, in particular when immunological strategies are used.</p>
url http://www.translational-medicine.com/content/1/1/13
work_keys_str_mv AT casamassimaaddolorata fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
AT brugnarasalvatore fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
AT freschiantonio fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
AT labiancaroberto fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
AT romaniniantonella fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
AT silenivanna fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
AT ravaiolialessandra fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
AT guidamichele fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
AT lorussovito fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
AT nannioriana fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
AT ridolfiruggero fibrinogenanovelpredictorofresponsivenessinmetastaticmelanomapatientstreatedwithbiochemotherapyimiitalianmelanomaintergrouptrial
_version_ 1725874504979185664